Geron to present data from IMerge Phase 3 trial at ASCO

Geron Corporation announced that data from the pivotal IMerge Phase 3 clinical trial evaluating the company’s first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes, was accepted for oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting. The data in the ASCO abstract will be embargoed per ASCO guidelines until May 25, 2023 at 5 p.m. Eastern Time. ASCO is taking place in Chicago, IL from June 2-6, 2023.